Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARTITUDE-6: Cilta-cel vs ASCT in Newly Diagnosed Multiple Myeloma
NCT05257083Phase 3Active, not recruiting
- Start
- Oct 2023
- Primary completion
- Jun 2033
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 16
01
Overview
A Phase 3 trial of ciltacabtagene autoleucel in multiple myeloma (MM). Started Oct 2023; status: active, not recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05257083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05257083.